Literature DB >> 21879787

Updates: Routine screening for antibodies to HIV-1, civilian applicants for U.S. military service and U.S. Armed Forces, active and reserve components.

.   

Abstract

During routine testing of civilian applicants for U.S. military service, the overall seroprevalence of antibodies to HIV-1 was lower in 2010 than in any year since 1990. Among members of the active components of the U.S. Army and Air Force, HIV-1 seroprevalences were higher in 2008-2010 than in recent prior years. Among members of the active components of the U.S. Navy and Marine Corps, the Marine Corps Reserve, and the Army National Guard, HIV-1 seroprevalences have slightly declined or remained relatively stable for at least ten years. In the reserve components of most of the service branches, it is difficult to discern long-term trends because of instability of seroprevalences observed in the relatively small numbers of reserve component members tested each year.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21879787

Source DB:  PubMed          Journal:  MSMR        ISSN: 2152-8217


  2 in total

1.  Short communication: Investigation of incident HIV infections among U.S. army soldiers deployed to Afghanistan and Iraq, 2001-2007.

Authors:  Paul T Scott; Shilpa Hakre; Otha Myles; Eric E Sanders-Buell; Gustavo H Kijak; Francine E McCutchan; Robert J O'Connell; Sheila A Peel; J Connor Eggleston; Warren B Sateren; Micaela Robb-McGrath; Robert L Mott; Steven K Tobler; Eileen Nolan; Bruno P Petruccelli; Nelson L Michael; Steven B Cersovsky
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-13       Impact factor: 2.205

2.  Cross-sectional assessment of prevalence and correlates of blood-borne and sexually-transmitted infections among Afghan National Army recruits.

Authors:  Catherine S Todd; Abdul Nasir; G Farooq Mansoor; Sayed M Sahibzada; Linda L Jagodzinski; Farzana Salimi; M Naim Khateri; Braden R Hale; R Vincent Barthel; Paul T Scott
Journal:  BMC Infect Dis       Date:  2012-08-21       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.